KRYS Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 32.42% compared to Krystal Biotech's net margin of -22.27%. Krystal Biotech's return on equity of 6.45% beat Alnylam Pharmaceuticals's return on equity of --.

Krystal Biotech has a consensus price target of $207.78, signalling upside risk potential of 29.47%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $299.11 which suggests that it could grow by 23.34%. Given that Krystal Biotech has higher upside potential than Alnylam Pharmaceuticals, analysts believe Krystal Biotech is more attractive than Alnylam Pharmaceuticals.

Krystal Biotech has a beta of 0.799, which suggesting that the stock is 20.116% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.319, suggesting its less volatile than the S&P 500 by 68.077%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $83.8M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $500.9M. Krystal Biotech's net income of $27.2M is higher than Alnylam Pharmaceuticals's net income of -$111.6M. Notably, Krystal Biotech's price-to-earnings ratio is 90.16x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 19.55x versus 14.68x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Bioventus has a net margin of 32.42% compared to Krystal Biotech's net margin of -3.47%. Krystal Biotech's return on equity of 6.45% beat Bioventus's return on equity of -18.97%.

Krystal Biotech has a consensus price target of $207.78, signalling upside risk potential of 29.47%. On the other hand Bioventus has an analysts' consensus of $15.00 which suggests that it could grow by 36.36%. Given that Bioventus has higher upside potential than Krystal Biotech, analysts believe Bioventus is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.799, which suggesting that the stock is 20.116% less volatile than S&P 500. In comparison Bioventus has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bioventus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Bioventus pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $83.8M, which are smaller than Bioventus quarterly revenues of $139M. Krystal Biotech's net income of $27.2M is higher than Bioventus's net income of -$4.8M. Notably, Krystal Biotech's price-to-earnings ratio is 90.16x while Bioventus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 19.55x versus 1.27x for Bioventus. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of 32.42% compared to Krystal Biotech's net margin of -4.76%. Krystal Biotech's return on equity of 6.45% beat Amicus Therapeutics's return on equity of -71.17%.

Krystal Biotech has a consensus price target of $207.78, signalling upside risk potential of 29.47%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 77.41%. Given that Amicus Therapeutics has higher upside potential than Krystal Biotech, analysts believe Amicus Therapeutics is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.799, which suggesting that the stock is 20.116% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $83.8M, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Krystal Biotech's net income of $27.2M is higher than Amicus Therapeutics's net income of -$6.7M. Notably, Krystal Biotech's price-to-earnings ratio is 90.16x while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 19.55x versus 6.00x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of 32.42% compared to Krystal Biotech's net margin of -236.04%. Krystal Biotech's return on equity of 6.45% beat Insmed's return on equity of --.

Krystal Biotech has a consensus price target of $207.78, signalling upside risk potential of 29.47%. On the other hand Insmed has an analysts' consensus of $88.25 which suggests that it could grow by 26.5%. Given that Krystal Biotech has higher upside potential than Insmed, analysts believe Krystal Biotech is more attractive than Insmed.

Krystal Biotech has a beta of 0.799, which suggesting that the stock is 20.116% less volatile than S&P 500. In comparison Insmed has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.328%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $83.8M, which are smaller than Insmed quarterly revenues of $93.4M. Krystal Biotech's net income of $27.2M is higher than Insmed's net income of -$220.5M. Notably, Krystal Biotech's price-to-earnings ratio is 90.16x while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 19.55x versus 32.03x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.